HOLLISTON, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (HBIO) today announced that it will be showcasing its latest product innovations at the Society for Neuroscience (SfN) ...
Detailed price information for Harvard Bioscience (HBIO-Q) from The Globe and Mail including charting and trades.
Full-year Revenue -- $86.6 million, an 8% decline primarily attributable to tariffs and delayed NIH funding. Full-year Adjusted EBITDA -- $8.1 million, up 12.5% year over year, attributed to cost ...
Reports preliminary fourth quarter revenue in line with guidance, gross margin at high end of guidance, and strong year over year adjusted EBITDA performance Expects year over year revenue growth and ...
Harvard Bioscience makes laboratory instruments and devices that support research in areas like drug discovery, therapy development, and preclinical testing. Its core products are used by universities ...
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. It operates ...
The MarketWatch News Department was not involved in the creation of this content. HOLLISTON, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the "Company" or ...
After serving as interim CFO at Harvard Bioscience for the past 11 months, Mark Frost has dropped his temporary tag and assumed the position at the Holliston-based biotech firm. Frost began his tenure ...
Fourth Quarter 2025 Revenues of $23.7M and Gross Margin of 59.7%Full Year 2025 Revenues of $86.6M and Gross Margin of 57.7%Interim CFO Mark Frost ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results